BACKGROUND: Although sexual dysfunction is common after hematopoietic stem cell transplantation (HCT), interventions to address sexual function are lacking. METHODS: We conducted a pilot study to assess the feasibility and preliminary efficacy of a multimodal intervention to address sexual dysfunction in allogeneic HCT survivors. Transplant clinicians screened HCT survivors ≥3 months post-HCT for sexual dysfunction causing distress. Those who screened positive attended monthly visits with a trained transplant clinician who: 1) performed an assessment of the causes of sexual dysfunction; 2) educated and empowered the patient to address his or her sexual concerns; and 3) implemented therapeutic interventions targeting the patient's needs. Feasibility was defined as having approximately 75% of patients who screened positive agreeing to participate and 80% attending at least 2 intervention visits. We administered the Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function and satisfaction measure, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and the Hospital Anxiety and Depression Scale (HADS) to evaluate sexual function, quality of life (QOL), and mood, respectively, at baseline and 6 months postintervention. RESULTS: Approximately 33.1% of patients (50 of 151 patients) screened positive for sexual dysfunction causing distress and 94.0% (47 of 50 patients) agreed to participate, with 100% attending 2 intervention visits. Participants reported improvements in satisfaction (P<.0001) and interest in sex (P<.0001), as well as orgasm (P<.0001), erectile function (P<.0001), vaginal lubrication (P = .0001), and vaginal discomfort (P = .0005). At baseline, approximately 32.6% of participants were not sexually active, compared with 6.5% after the intervention (P = .0005). Participants reported improvement in their QOL (P<.0001), depression (P = .0002), and anxiety (P = .0019). CONCLUSIONS: A multimodal intervention to address sexual dysfunction integrated within the transplant clinic is feasible with encouraging preliminary efficacy for improving sexual function, QOL, and mood in HCT survivors. Cancer 2018;124:2438-46.
BACKGROUND: Although sexual dysfunction is common after hematopoietic stem cell transplantation (HCT), interventions to address sexual function are lacking. METHODS: We conducted a pilot study to assess the feasibility and preliminary efficacy of a multimodal intervention to address sexual dysfunction in allogeneic HCT survivors. Transplant clinicians screened HCT survivors ≥3 months post-HCT for sexual dysfunction causing distress. Those who screened positive attended monthly visits with a trained transplant clinician who: 1) performed an assessment of the causes of sexual dysfunction; 2) educated and empowered the patient to address his or her sexual concerns; and 3) implemented therapeutic interventions targeting the patient's needs. Feasibility was defined as having approximately 75% of patients who screened positive agreeing to participate and 80% attending at least 2 intervention visits. We administered the Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function and satisfaction measure, the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and the Hospital Anxiety and Depression Scale (HADS) to evaluate sexual function, quality of life (QOL), and mood, respectively, at baseline and 6 months postintervention. RESULTS: Approximately 33.1% of patients (50 of 151 patients) screened positive for sexual dysfunction causing distress and 94.0% (47 of 50 patients) agreed to participate, with 100% attending 2 intervention visits. Participants reported improvements in satisfaction (P<.0001) and interest in sex (P<.0001), as well as orgasm (P<.0001), erectile function (P<.0001), vaginal lubrication (P = .0001), and vaginal discomfort (P = .0005). At baseline, approximately 32.6% of participants were not sexually active, compared with 6.5% after the intervention (P = .0005). Participants reported improvement in their QOL (P<.0001), depression (P = .0002), and anxiety (P = .0019). CONCLUSIONS: A multimodal intervention to address sexual dysfunction integrated within the transplant clinic is feasible with encouraging preliminary efficacy for improving sexual function, QOL, and mood in HCT survivors. Cancer 2018;124:2438-46.
Authors: Alois Gratwohl; Helen Baldomero; Mahmoud Aljurf; Marcelo C Pasquini; Luis Fernando Bouzas; Ayami Yoshimi; Jeff Szer; Jeff Lipton; Alvin Schwendener; Michael Gratwohl; Karl Frauendorfer; Dietger Niederwieser; Mary Horowitz; Yoshihisa Kodera Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: Areej R El-Jawahri; Lara N Traeger; Kailyn Kuzmuk; Justin R Eusebio; Harry B Vandusen; Jennifer A Shin; Tanya Keenan; Emily R Gallagher; Joseph A Greer; William F Pirl; Vicki A Jackson; Karen K Ballen; Thomas R Spitzer; Timothy A Graubert; Steven L McAfee; Bimalangshu R Dey; Yi-Bin A Chen; Jennifer S Temel Journal: Cancer Date: 2014-12-02 Impact factor: 6.860
Authors: Rachel Phelan; Annie Im; Rebecca L Hunter; Yoshihiro Inamoto; Maria Teresa Lupo-Stanghellini; Alicia Rovo; Sherif M Badawy; Linda Burns; Hesham Eissa; Hemant S Murthy; Pinki Prasad; Akshay Sharma; Elizabeth Suelzer; Vaibhav Agrawal; Mahmoud Aljurf; Karen Baker; Grzegorz W Basak; David Buchbinder; Zachariah DeFilipp; Lana Desnica Grkovic; Ajoy Dias; Hermann Einsele; Michael L Eisenberg; Narendranath Epperla; Nosha Farhadfar; Arthur Flatau; Robert Peter Gale; Hildegard Greinix; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Kareem Jamani; Dipnarine Maharaj; John Murray; Seema Naik; Sunita Nathan; Steven Pavletic; Zinaida Peric; Drazen Pulanic; Richard Ross; Andrea Salonia; Isabel Sanchez-Ortega; Bipin N Savani; Tal Schechter; Ami J Shah; Stephanie M Smith; John A Snowden; Amir Steinberg; Douglas Tremblay; Sarah C Vij; Lauren Walker; Daniel Wolff; Jean A Yared; Hélène Schoemans; André Tichelli Journal: Transplant Cell Ther Date: 2021-10-29
Authors: Rachel Phelan; Annie Im; Hélène Schoemans; André Tichelli; Rebecca L Hunter; Yoshihiro Inamoto; Maria Teresa Lupo-Stanghellini; Alicia Rovo; Sherif M Badawy; Linda Burns; Hesham Eissa; Hemant S Murthy; Pinki Prasad; Akshay Sharma; Elizabeth Suelzer; Vaibhav Agrawal; Mahmoud Aljurf; Karen Baker; Grzegorz W Basak; David Buchbinder; Zachariah DeFilipp; Lana Desnica Grkovic; Ajoy Dias; Hermann Einsele; Michael L Eisenberg; Narendranath Epperla; Nosha Farhadfar; Arthur Flatau; Robert Peter Gale; Hildegard Greinix; Betty K Hamilton; Shahrukh Hashmi; Peiman Hematti; Kareem Jamani; Dipnarine Maharaj; John Murray; Seema Naik; Sunita Nathan; Steven Pavletic; Zinaida Peric; Drazen Pulanic; Richard Ross; Andrea Salonia; Isabel Sanchez-Ortega; Bipin N Savani; Tal Schechter; Ami J Shah; Stephanie M Smith; John A Snowden; Amir Steinberg; Douglas Tremblay; Sarah C Vij; Lauren Walker; Daniel Wolff; Jean A Yared Journal: Bone Marrow Transplant Date: 2022-05-06 Impact factor: 5.174
Authors: Brindha Pillay; Maria Ftanou; David Ritchie; Yvonne Panek-Hudson; Michael Jefford; Teresa Garcia; Cassandra Shields; Jo Gniel; Jo Phipps-Nelson; Allison Drosdowsky; Sarah Blaschke; Steve Ellen Journal: BMJ Open Date: 2020-10-31 Impact factor: 2.692
Authors: Karen L Syrjala; Hélène Schoemans; Jean C Yi; Shelby L Langer; Ahona Mukherjee; Lynn Onstad; Stephanie J Lee Journal: Transplant Cell Ther Date: 2020-09-29